|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2000-5-12
|
|
pubmed:abstractText |
Thirty-seven patients with multiple myeloma (stage II and III, 65% increased beta2-microglobulin level) were prospectively treated with a median of 3.7 VAD courses (range 2-8) followed by cyclophosphamide (6 g/m2) in conjunction with G-CSF (5 microg/kg filgrastrim (n = 14), or 3.5 microg/kg lenograstrim (n = 22)), and peripheral stem cell (PSC) isolation. After regeneration this was followed by one EDAP course and high-dose melphalan (HDM, 200 mg/m2) in combination with re-infusion of PSC. Adequate stem cell mobilization was obtained with both G-CSF regimens. A median of 41x10(6) CD34+ cells/kg (range 4.5-161) was collected in a median of 1.6 leukapheresis procedures following filgrastrim (n = 14) and 24x10(6) CD34+ cells/kg (range 2. 3-80) in a median of 1.7 leukapheresis procedures following lenograstrim (n = 22) which indicated no significant difference (P = 0.24) between both G-CSF regimens. A rapid hematological recovery was obtained after HDM with reinfusion of a median of 9.3x10(6) CD34+ cells/kg. After the total courses the overall response was 84% with a complete remission rate of 30%. Currently the median overall survival is 44.0 months (95% CI 38.9-49.1) with a median follow-up of 33 months (range 3-51) and a median event-free survival of 29.0 months (95% CI 25.3-32.7) (n = 33). Post transplantation a high incidence of oligloclonal serum immunoglobulins (Igs) was observed. In 73% of the patients new oligoclonal or monoclonal serum bands were noticed 3 months post transplantation. IgG-lambda and IgG-kappa bands predominated. In 48% of the cases the oligoclonal Igs disappeared after a median follow-up of 22 months (range 8-36), whereas in 52% of the cases the oligoclonal Igs persisted with a median follow-up of 31 months (range 21-45), which did not correlate with a significant difference in overall, and event-free survival between both subgroups.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Filgrastim,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin A,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin M,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/beta 2-Microglobulin,
http://linkedlifedata.com/resource/pubmed/chemical/lenograstim
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
723-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10745257-Adjuvants, Immunologic,
pubmed-meshheading:10745257-Adult,
pubmed-meshheading:10745257-Aged,
pubmed-meshheading:10745257-Antigens, CD,
pubmed-meshheading:10745257-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10745257-Cisplatin,
pubmed-meshheading:10745257-Cyclophosphamide,
pubmed-meshheading:10745257-Cytarabine,
pubmed-meshheading:10745257-Dexamethasone,
pubmed-meshheading:10745257-Disease-Free Survival,
pubmed-meshheading:10745257-Doxorubicin,
pubmed-meshheading:10745257-Etoposide,
pubmed-meshheading:10745257-Female,
pubmed-meshheading:10745257-Follow-Up Studies,
pubmed-meshheading:10745257-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:10745257-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10745257-Humans,
pubmed-meshheading:10745257-Immunoglobulin A,
pubmed-meshheading:10745257-Immunoglobulin G,
pubmed-meshheading:10745257-Immunoglobulin M,
pubmed-meshheading:10745257-Male,
pubmed-meshheading:10745257-Middle Aged,
pubmed-meshheading:10745257-Multiple Myeloma,
pubmed-meshheading:10745257-Neoplasm Staging,
pubmed-meshheading:10745257-Recombinant Proteins,
pubmed-meshheading:10745257-Time Factors,
pubmed-meshheading:10745257-Transplantation, Autologous,
pubmed-meshheading:10745257-Vincristine,
pubmed-meshheading:10745257-beta 2-Microglobulin
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
|
|
pubmed:affiliation |
Department of Hematology, University Hospital Groningen, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
